<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02762838</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-055-3</org_study_id>
    <nct_id>NCT02762838</nct_id>
  </id_info>
  <brief_title>Comparative Clinical Trial of Efficacy and Safety of BCD-055 and Remicade® in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis</brief_title>
  <official_title>International Multi-center Comparative Double-blind Randomized Clinical Trial of Efficacy and Safety of BCD-055 (JSC &quot;BIOCAD&quot;, Russia) and Remicade® in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BCD-055-3 is international multi-center comparative double-blind randomized clinical trial of
      efficacy and safety of BCD-055 (JSC &quot;BIOCAD&quot;, Russia) and Remicade® in combination with
      methotrexate in patients with active rheumatoid arthritis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratio of patients with ACR20 response after 14 weeks of therapy</measure>
    <time_frame>Week 14</time_frame>
    <description>Ratio of patients who developed a decrease in American College of Rheumatologists (ACR) score by 20% or more after 14 weeks of therapy with study drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ratio of patients with ACR20 response after 30 and 54 weeks of therapy</measure>
    <time_frame>Week 30, Week 54</time_frame>
    <description>Ratio of patients who developed a decrease in American College of Rheumatologists (ACR) score by 20% or more after 30 and 54 weeks of therapy with study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of patients with ACR50 and 70 response after 14, 30 and 54 weeks of therapy</measure>
    <time_frame>Week 14, Week 30, Week 54</time_frame>
    <description>Ratio of patients who developed a decrease in American College of Rheumatologists (ACR) score by 50% or more and by 70% or more after 14, 30 and 54 weeks of therapy with study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of patients with low activity of rheumatoid arthritis according to index DAS28-CRP(4) after 14, 30 and 54 weeks of therapy</measure>
    <time_frame>Week 14, Week 30, Week 54</time_frame>
    <description>Ratio of patients with low activity of rheumatoid arthritis according to index Disease Activity Score 28 - C-reactive protein (DAS28-CRP(4), score 2.6-3.2) after 14, 30 and 54 weeks of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of patients with low activity of rheumatoid arthritis according to index CDAI after 14, 30 and 54 weeks of therapy</measure>
    <time_frame>Week 14, Week 30, Week 54</time_frame>
    <description>Ratio of patients with low activity of rheumatoid arthritis according to Clinical Disease Activity Index (CDAI, score 2.9-10.0) after 14, 30 and 54 weeks of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of patients with low activity of rheumatoid arthritis according to index SDAI after 14, 30 and 54 weeks of therapy</measure>
    <time_frame>Week 14, Week 30, Week 54</time_frame>
    <description>Ratio of patients with low activity of rheumatoid arthritis according to Simplified Disease Activity Index (SDAI, score 3.4-11.0) after 14, 30 and 54 weeks of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of patients with remission of rheumatoid arthritis according to index DAS28 after 14, 30 and 54 weeks of therapy</measure>
    <time_frame>Week 14, Week 30, Week 54</time_frame>
    <description>Ratio of patients with remission of rheumatoid arthritis according to index Disease Activity Score 28 (DAS28, score less than 2.6) after 14, 30 and 54 weeks of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of patients with remission of rheumatoid arthritis according to index CDAI after 14, 30 and 54 weeks of therapy</measure>
    <time_frame>Week 14, Week 30, Week 54</time_frame>
    <description>Ratio of patients with remission of rheumatoid arthritis according to Clinical Disease Activity Index (CDAI, score 0.0-2.8) after 14, 30 and 54 weeks of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of patients with remission of rheumatoid arthritis according to index SDAI after 14, 30 and 54 weeks of therapy</measure>
    <time_frame>Week 14, Week 30, Week 54</time_frame>
    <description>Ratio of patients with remission of rheumatoid arthritis according to Simplified Disease Activity Index (SDAI, score 0.0-3.3) after 14, 30 and 54 weeks of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of patients with remission of rheumatoid arthritis according to ACR-EULAR criteria after 14, 30 and 54 weeks of therapy</measure>
    <time_frame>Week 14, Week 30, Week 54</time_frame>
    <description>Ratio of patients with low activity of rheumatoid arthritis according to American College of Rheumatologists (ACR)/ European league Against Rheumatism (EULAR) after 14, 30 and 54 weeks of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean SF-36 score at screening and after 14, 30 and 54 weeks of therapy</measure>
    <time_frame>Screening, Week 14, Week 30, Week 54</time_frame>
    <description>Mean score of quality of life as assessed by Short Form-36 (SF-36) at screening and after 14, 30 and 54 weeks of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP</measure>
    <time_frame>Screening, Week 14, Week 30, Week 54</time_frame>
    <description>Dynamics of blood level of C-reactive protein (CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ESR</measure>
    <time_frame>Screening, Week 14, Week 30, Week 54</time_frame>
    <description>Dynamics of Erythrocyte Sedimentation Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Roentgenologic characteristics of abnormal joints after 54 weeks of therapy</measure>
    <time_frame>Week 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of AE/SAE</measure>
    <time_frame>54 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of AE 3-4 grade CTCAE</measure>
    <time_frame>54 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of early withdrawals due to AE/SAE</measure>
    <time_frame>54 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who developed binding and neutralizing antibodies to infliximab</measure>
    <time_frame>Screening, Week 14, Week 30, Week 54</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">426</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>BCD-055</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will receive BCD-055 in a dose of 3 mg/kg on Week 0, Week 2, Week 6, Week 14, Week 22, Week 30, Week 38, Week 46, Week 54.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remicade®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will receive Remicade® in a dose of 3 mg/kg on Week 0, Week 2, Week 6, Week 14, Week 22, Week 30, Week 38, Week 46, Week 54.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCD-055</intervention_name>
    <description>BCD-055 is infliximab biosimilar</description>
    <arm_group_label>BCD-055</arm_group_label>
    <other_name>infliximab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Remicade®</intervention_name>
    <arm_group_label>Remicade®</arm_group_label>
    <other_name>infliximab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>All patients will receive methotrexate in a dose from 10 to 25 mg per week.</description>
    <arm_group_label>BCD-055</arm_group_label>
    <arm_group_label>Remicade®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folic acid</intervention_name>
    <description>All patients will receive folic acid in a dose of 5 mg per week.</description>
    <arm_group_label>BCD-055</arm_group_label>
    <arm_group_label>Remicade®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Active rheumatoid arthritis according to criteria of American College of
             Rheumatologists (2010), that was diagnosed at least 6 months prior to screening.

          -  Active rheumatoid arthritis at screening despite of therapy with methotrexate for 3
             last months.

          -  Use of methotrexate in stable dose for at least 4 weeks before screening (10-25 mg per
             week).

          -  History of ineffective treatment with basic antiinflammatory drugs (including
             methotrexate).

        Exclusion Criteria:

          -  Previous therapy of rheumatoid arthritis with monoclonal antibodies (including
             anti-tumor necrosis factor drugs)

          -  Felty's syndrome

          -  Functional status - class IV according to ACR classification (1991)

          -  Low activity of rheumatoid arthritis (DAS28-CRP(4) index less than 3.2)

          -  Patient needs corticosteroids in a dose more than 10 mg (recalculated to prednisolone)
             before signing informed consent.

          -  Patients needs equal of less than 10 mg prednisolone but the dose was not stable for
             last 4 weeks prior to infliximab treatment

          -  Prior use of disease-modifying antirheumatic drugs including methotrexate,
             sulfasalazin, chloroquine or hydroxychloroquine for up to 4 weeks before
             randomization.

          -  Prior use of alkylating agents for up to 12 months prior to signing informed consent.

          -  Intraarticular use of corticosteroids for up to 4 weeks before randomization.

          -  Prior use of live or attenuated vaccines for up to 8 weeks before signing informed
             consent.

          -  Diagnosis of tuberculosis.

          -  Body mass more than 130 kg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman Ivanov, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>JSC BIOCAD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>State Budgetary Higher Vocational Education Institution I.M. Sechenov First Moscow State Medical University</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North-Western State Medical University n.a. I.I.Mechnikov</name>
      <address>
        <city>St.Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2016</study_first_submitted>
  <study_first_submitted_qc>May 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2016</study_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

